AstraZeneca

We are at the forefront of protein engineering to deliver next-generation targeted therapeutics across disease areas. Building on our long history of antibody discovery and protein engineering, we have established a unique multispecific drug discovery platform with the aim of delivering the next generation of medicines. Learn more about our proprietary multispecifics technology here: https://learn.az/6048qf7h0 #WhatScienceCanDo

It’s a historic time for the rare disease community in Europe. While more than 30 countries across the continent have national rare disease plans in place or under development, the new European Parliament and Commission have begun considering policies that could either protect and enhance hard earned progress or erode it. We’re joined by leaders from across the rare disease community at the World Orphan Drug Congress Europe to explore how policies and practices across diverse nations can enable more timely, more accessible, and more equitable care for more people living with rare diseases. Discover more: https://learn.az/6047qFp29 #Alexion #WODCEurope2024

This World Amyloidosis Day, we’re emphasising the urgent need for earlier diagnosis of amyloidosis and greater awareness of this progressive, life-threatening disease. Misdiagnosis and delayed screening when signs of the condition are present pose significant challenges and often prevent patients from receiving timely access to care. Explore how healthcare innovation and proactive strategies can transform outcomes for those living with amyloidosis: https://learn.az/6048qnZQj #WorldAmyloidosisDay

Neurodiversity is a reality for approximately 15-20% of the global population, and at AstraZeneca, we embrace and celebrate these unique perspectives. Our global TH!NK Employee Resource Group (ERG) is dedicated to supporting our neurodiverse employees by offering invaluable resources, guidance, and a supportive community. Discover the impact the TH!NK ERG has on our team members and how it helps them excel in their roles. Join us in celebrating diversity and inclusion at AstraZeneca. Together, we're making a difference. Learn more about our ERGs: https://learn.az/6047qayR1 #LifeatAZ #ERG

TrailblAZers with Professor Charlotte Hespe In this month’s episode of TrailblAZers, we speak with Professor Charlotte Hespe, the Head of General Practice and Primary Care Research, Sydney School of Medicine, at Notre Dame University. Professor Hespe is principal GP and practice owner of Glebe Family Medical Practice in Sydney’s inner-west and is also a researcher, mentor, primary health leader, and advocate for better primary care. Tune in as Professor Hespe discusses the vital role of general practice in Australian healthcare, improving chronic disease management, enhancing healthcare for First Nations Australians, and her vision of the future of primary care. #EarlierFasterFairer   #NoPatientLeftBehind  #TrailblAZers

With high and rising global burden, chronic kidney disease (CKD) is expected to become the world’s fifth leading cause of mortality by 2040. The time for change is now. With the NCD Alliance Global Week for Action on NCDs (non-communicable diseases) underway, it is essential that we continue to elevate CKD as a priority NCD, advocating for stronger global and national commitments to address this growing burden. Discover how early diagnosis and better access to treatment and care can make a change for millions living with CKD in this Devex produced event, co-sponsored by AstraZeneca and Boehringer Ingelheim. https://learn.az/6040qsiYA #ForKidneyHealth #LeadOnNCDs #ActOnNCDs

Quality and timely healthcare remain out of reach for too many people, even though health is the foundation of a sustainable and thriving society. Stefan Werner Weber, Vice President, Head of Global Policy, Advocacy and Health Equity at AstraZeneca, discusses this challenge in ‘Health: a Political Choice - Building Resilience and Trust’ calling for concerted efforts to tackle the issue by harnessing data, digital technologies and the power of public-private partnership. Everyone, everywhere, deserves the chance to live a healthy life, regardless of who they are or where they were born. At AstraZeneca, we are working to better understand factors that drive poor health outcomes among different populations and partnering with health systems and communities to bring tailored solutions to close equity gaps. #HealthEquity #InterConnectedHealth #Sustainability

Someone dies prematurely from a non-communicable disease (NCD), like a respiratory or cardiovascular disease, every two seconds, even though these diseases are largely preventable. As part of the World Health Summit, Iskra Reic, Executive Vice President, Vaccines & Immune Therapies, published an article in ‘Health: a Political Choice - Building Resilience and Trust’ calling for investment, innovation, collaboration and evidence-based policy reform, including: - Acting urgently to address the growing burden of NCDs, by looking beyond individuals and health systems, to the impact on economies and the climate-health nexus. - Acting early by shifting from ‘sick care’ to ‘health care’ that focuses on screening and early detection and treatment of disease. - Acting for equity, by understanding the barriers to healthcare that certain communities face and ensuring their needs are central to the delivery of care At AstraZeneca, we are working to address the growing burden of NCDs in line with the United Nations Sustainable Development Goals. The 2025 High-Level Meeting on NCDs provides a critical opportunity for concerted and collective action. Link to the full article: https://learn.az/6046qTv74 #WHS2024 #InterConnectedHealth #NCDs

From understanding disease at a molecular level to collaborating on global healthcare solutions, we harness the power of what science can do to make a difference for people, society and the planet. By focusing on small details, we can create significant impacts that lead to transformative outcomes. Our mission is to innovate and create accessible medicines that transform lives. Join us on this journey of discovery and see how we can push the boundaries of science together. #WhatScienceCanDo

We are pleased to announce the appointment of Ram Mudaliar to the Society for Clinical Data Management (SCDM) Global Board of Trustees for the term 2025-2027. Having rich experience in clinical data management, Ram will bring valuable insights and strategic leadership to global clinical data management community, driving innovation in the clinical space.   Ram’s broad scope of responsibilities as a trustee will include – collaboration with industry leaders, SCDM footprint expansion, building partnerships with institutions and startups, leading efforts in generating impactful research and white papers towards best practices and education, thereby fostering innovation, and enhancing patient outcomes.   Please join us in congratulating Ram for this fantastic accomplishment. We wish him success in this role and believe that his expertise will be instrumental in bolstering our Bold Ambition 2030. Natalie Fishburn | David Carruthers | Sarah Clark | Siva Kumar Padmanabhan | Veena Rajan | Gaurav Sharma